nodes	percent_of_prediction	percent_of_DWPC	metapath
Vandetanib—RET—autonomic nervous system—Gilles de la Tourette syndrome	0.0672	0.0672	CbGeAlD
Vandetanib—EPHA8—nervous system—Gilles de la Tourette syndrome	0.0161	0.0161	CbGeAlD
Vandetanib—EPHA8—central nervous system—Gilles de la Tourette syndrome	0.0155	0.0155	CbGeAlD
Vandetanib—EPHA5—midbrain—Gilles de la Tourette syndrome	0.0152	0.0152	CbGeAlD
Vandetanib—EPHA6—nervous system—Gilles de la Tourette syndrome	0.0134	0.0134	CbGeAlD
Vandetanib—EPHA6—central nervous system—Gilles de la Tourette syndrome	0.0129	0.0129	CbGeAlD
Vandetanib—LTK—brain—Gilles de la Tourette syndrome	0.0128	0.0129	CbGeAlD
Vandetanib—STK35—midbrain—Gilles de la Tourette syndrome	0.0126	0.0126	CbGeAlD
Vandetanib—TYRO3—nervous system—Gilles de la Tourette syndrome	0.0125	0.0125	CbGeAlD
Vandetanib—EPHA5—nervous system—Gilles de la Tourette syndrome	0.0125	0.0125	CbGeAlD
Vandetanib—LYN—nervous system—Gilles de la Tourette syndrome	0.0124	0.0124	CbGeAlD
Vandetanib—EPHA8—brain—Gilles de la Tourette syndrome	0.0123	0.0123	CbGeAlD
Vandetanib—BMPR1B—nervous system—Gilles de la Tourette syndrome	0.0122	0.0122	CbGeAlD
Vandetanib—MAP3K19—nervous system—Gilles de la Tourette syndrome	0.0122	0.0122	CbGeAlD
Vandetanib—TYRO3—central nervous system—Gilles de la Tourette syndrome	0.012	0.012	CbGeAlD
Vandetanib—EPHA5—central nervous system—Gilles de la Tourette syndrome	0.012	0.012	CbGeAlD
Vandetanib—LYN—central nervous system—Gilles de la Tourette syndrome	0.0119	0.0119	CbGeAlD
Vandetanib—BMPR1B—central nervous system—Gilles de la Tourette syndrome	0.0118	0.0118	CbGeAlD
Vandetanib—MAP3K19—central nervous system—Gilles de la Tourette syndrome	0.0118	0.0118	CbGeAlD
Vandetanib—RIPK2—midbrain—Gilles de la Tourette syndrome	0.0116	0.0117	CbGeAlD
Vandetanib—ERBB3—midbrain—Gilles de la Tourette syndrome	0.0111	0.0112	CbGeAlD
Vandetanib—MKNK1—midbrain—Gilles de la Tourette syndrome	0.0105	0.0105	CbGeAlD
Vandetanib—STK35—nervous system—Gilles de la Tourette syndrome	0.0104	0.0104	CbGeAlD
Vandetanib—RET—midbrain—Gilles de la Tourette syndrome	0.0103	0.0103	CbGeAlD
Vandetanib—AXL—midbrain—Gilles de la Tourette syndrome	0.0103	0.0103	CbGeAlD
Vandetanib—EPHA6—brain—Gilles de la Tourette syndrome	0.0103	0.0103	CbGeAlD
Vandetanib—PLK4—brain—Gilles de la Tourette syndrome	0.0101	0.0101	CbGeAlD
Vandetanib—STK35—central nervous system—Gilles de la Tourette syndrome	0.01	0.01	CbGeAlD
Vandetanib—SLK—midbrain—Gilles de la Tourette syndrome	0.00991	0.00992	CbGeAlD
Vandetanib—FYN—midbrain—Gilles de la Tourette syndrome	0.00964	0.00964	CbGeAlD
Vandetanib—TYRO3—brain—Gilles de la Tourette syndrome	0.00953	0.00953	CbGeAlD
Vandetanib—EPHA5—brain—Gilles de la Tourette syndrome	0.00953	0.00953	CbGeAlD
Vandetanib—FMO1—nervous system—Gilles de la Tourette syndrome	0.0095	0.0095	CbGeAlD
Vandetanib—LYN—brain—Gilles de la Tourette syndrome	0.00948	0.00948	CbGeAlD
Vandetanib—TEK—midbrain—Gilles de la Tourette syndrome	0.00942	0.00942	CbGeAlD
Vandetanib—MAP4K5—midbrain—Gilles de la Tourette syndrome	0.00942	0.00942	CbGeAlD
Vandetanib—IRAK4—nervous system—Gilles de la Tourette syndrome	0.00935	0.00935	CbGeAlD
Vandetanib—BMPR1B—brain—Gilles de la Tourette syndrome	0.00933	0.00934	CbGeAlD
Vandetanib—MAP3K19—brain—Gilles de la Tourette syndrome	0.00933	0.00934	CbGeAlD
Vandetanib—ERBB3—nervous system—Gilles de la Tourette syndrome	0.00916	0.00917	CbGeAlD
Vandetanib—FMO1—central nervous system—Gilles de la Tourette syndrome	0.00914	0.00915	CbGeAlD
Vandetanib—IRAK4—central nervous system—Gilles de la Tourette syndrome	0.009	0.009	CbGeAlD
Vandetanib—EPHB6—midbrain—Gilles de la Tourette syndrome	0.009	0.009	CbGeAlD
Vandetanib—ERBB3—central nervous system—Gilles de la Tourette syndrome	0.00882	0.00883	CbGeAlD
Vandetanib—YES1—midbrain—Gilles de la Tourette syndrome	0.0087	0.0087	CbGeAlD
Vandetanib—MKNK1—nervous system—Gilles de la Tourette syndrome	0.0086	0.00861	CbGeAlD
Vandetanib—FGR—nervous system—Gilles de la Tourette syndrome	0.0085	0.0085	CbGeAlD
Vandetanib—RET—nervous system—Gilles de la Tourette syndrome	0.0085	0.0085	CbGeAlD
Vandetanib—AXL—nervous system—Gilles de la Tourette syndrome	0.00846	0.00847	CbGeAlD
Vandetanib—MKNK1—central nervous system—Gilles de la Tourette syndrome	0.00828	0.00829	CbGeAlD
Vandetanib—FMO3—nervous system—Gilles de la Tourette syndrome	0.00821	0.00821	CbGeAlD
Vandetanib—FGR—central nervous system—Gilles de la Tourette syndrome	0.00818	0.00819	CbGeAlD
Vandetanib—RET—central nervous system—Gilles de la Tourette syndrome	0.00818	0.00819	CbGeAlD
Vandetanib—AXL—central nervous system—Gilles de la Tourette syndrome	0.00815	0.00815	CbGeAlD
Vandetanib—STK35—brain—Gilles de la Tourette syndrome	0.00794	0.00794	CbGeAlD
Vandetanib—FYN—nervous system—Gilles de la Tourette syndrome	0.00792	0.00793	CbGeAlD
Vandetanib—FMO3—central nervous system—Gilles de la Tourette syndrome	0.0079	0.00791	CbGeAlD
Vandetanib—MAP4K5—nervous system—Gilles de la Tourette syndrome	0.00774	0.00775	CbGeAlD
Vandetanib—TEK—nervous system—Gilles de la Tourette syndrome	0.00774	0.00775	CbGeAlD
Vandetanib—ABL2—brain—Gilles de la Tourette syndrome	0.00773	0.00774	CbGeAlD
Vandetanib—MAP2K5—midbrain—Gilles de la Tourette syndrome	0.0077	0.0077	CbGeAlD
Vandetanib—KDR—midbrain—Gilles de la Tourette syndrome	0.0077	0.0077	CbGeAlD
Vandetanib—FYN—central nervous system—Gilles de la Tourette syndrome	0.00763	0.00763	CbGeAlD
Vandetanib—EGFR—brain—Gilles de la Tourette syndrome	0.00755	0.00755	CbGeAlD
Vandetanib—TEK—central nervous system—Gilles de la Tourette syndrome	0.00745	0.00746	CbGeAlD
Vandetanib—MAP4K5—central nervous system—Gilles de la Tourette syndrome	0.00745	0.00746	CbGeAlD
Vandetanib—EPHB6—nervous system—Gilles de la Tourette syndrome	0.0074	0.0074	CbGeAlD
Vandetanib—FLT4—brain—Gilles de la Tourette syndrome	0.00736	0.00736	CbGeAlD
Vandetanib—RIPK2—brain—Gilles de la Tourette syndrome	0.00732	0.00732	CbGeAlD
Vandetanib—VEGFA—brain—Gilles de la Tourette syndrome	0.0073	0.0073	CbGeAlD
Vandetanib—FMO1—brain—Gilles de la Tourette syndrome	0.00726	0.00726	CbGeAlD
Vandetanib—YES1—nervous system—Gilles de la Tourette syndrome	0.00715	0.00715	CbGeAlD
Vandetanib—IRAK4—brain—Gilles de la Tourette syndrome	0.00715	0.00715	CbGeAlD
Vandetanib—EPHB6—central nervous system—Gilles de la Tourette syndrome	0.00712	0.00713	CbGeAlD
Vandetanib—STK10—nervous system—Gilles de la Tourette syndrome	0.00709	0.00709	CbGeAlD
Vandetanib—ERBB3—brain—Gilles de la Tourette syndrome	0.007	0.00701	CbGeAlD
Vandetanib—YES1—central nervous system—Gilles de la Tourette syndrome	0.00688	0.00689	CbGeAlD
Vandetanib—SRC—nervous system—Gilles de la Tourette syndrome	0.00688	0.00688	CbGeAlD
Vandetanib—STK10—central nervous system—Gilles de la Tourette syndrome	0.00682	0.00682	CbGeAlD
Vandetanib—PDGFRB—midbrain—Gilles de la Tourette syndrome	0.00666	0.00666	CbGeAlD
Vandetanib—SRC—central nervous system—Gilles de la Tourette syndrome	0.00662	0.00663	CbGeAlD
Vandetanib—MKNK1—brain—Gilles de la Tourette syndrome	0.00658	0.00658	CbGeAlD
Vandetanib—RET—brain—Gilles de la Tourette syndrome	0.0065	0.0065	CbGeAlD
Vandetanib—FGR—brain—Gilles de la Tourette syndrome	0.0065	0.0065	CbGeAlD
Vandetanib—AXL—brain—Gilles de la Tourette syndrome	0.00647	0.00647	CbGeAlD
Vandetanib—MAP2K5—nervous system—Gilles de la Tourette syndrome	0.00633	0.00633	CbGeAlD
Vandetanib—KDR—nervous system—Gilles de la Tourette syndrome	0.00633	0.00633	CbGeAlD
Vandetanib—FMO3—brain—Gilles de la Tourette syndrome	0.00627	0.00628	CbGeAlD
Vandetanib—SLK—brain—Gilles de la Tourette syndrome	0.00623	0.00623	CbGeAlD
Vandetanib—MAP2K5—central nervous system—Gilles de la Tourette syndrome	0.00609	0.00609	CbGeAlD
Vandetanib—KDR—central nervous system—Gilles de la Tourette syndrome	0.00609	0.00609	CbGeAlD
Vandetanib—FYN—brain—Gilles de la Tourette syndrome	0.00606	0.00606	CbGeAlD
Vandetanib—ABL1—midbrain—Gilles de la Tourette syndrome	0.00594	0.00594	CbGeAlD
Vandetanib—MAP4K5—brain—Gilles de la Tourette syndrome	0.00592	0.00592	CbGeAlD
Vandetanib—TEK—brain—Gilles de la Tourette syndrome	0.00592	0.00592	CbGeAlD
Vandetanib—EPHB6—brain—Gilles de la Tourette syndrome	0.00566	0.00566	CbGeAlD
Vandetanib—PDGFRB—nervous system—Gilles de la Tourette syndrome	0.00548	0.00548	CbGeAlD
Vandetanib—YES1—brain—Gilles de la Tourette syndrome	0.00547	0.00547	CbGeAlD
Vandetanib—STK10—brain—Gilles de la Tourette syndrome	0.00542	0.00542	CbGeAlD
Vandetanib—PDGFRB—central nervous system—Gilles de la Tourette syndrome	0.00527	0.00527	CbGeAlD
Vandetanib—SRC—brain—Gilles de la Tourette syndrome	0.00526	0.00526	CbGeAlD
Vandetanib—ORM1—nervous system—Gilles de la Tourette syndrome	0.00514	0.00514	CbGeAlD
Vandetanib—ORM1—central nervous system—Gilles de la Tourette syndrome	0.00495	0.00495	CbGeAlD
Vandetanib—ABL1—nervous system—Gilles de la Tourette syndrome	0.00488	0.00488	CbGeAlD
Vandetanib—KDR—brain—Gilles de la Tourette syndrome	0.00484	0.00484	CbGeAlD
Vandetanib—MAP2K5—brain—Gilles de la Tourette syndrome	0.00484	0.00484	CbGeAlD
Vandetanib—ABL1—central nervous system—Gilles de la Tourette syndrome	0.0047	0.0047	CbGeAlD
Vandetanib—PDGFRB—brain—Gilles de la Tourette syndrome	0.00419	0.00419	CbGeAlD
Vandetanib—ABCG2—midbrain—Gilles de la Tourette syndrome	0.00374	0.00375	CbGeAlD
Vandetanib—ABL1—brain—Gilles de la Tourette syndrome	0.00373	0.00373	CbGeAlD
Vandetanib—ALB—brain—Gilles de la Tourette syndrome	0.00344	0.00344	CbGeAlD
Vandetanib—ABCC1—brain—Gilles de la Tourette syndrome	0.00284	0.00284	CbGeAlD
Vandetanib—ABCG2—brain—Gilles de la Tourette syndrome	0.00235	0.00235	CbGeAlD
Vandetanib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00214	0.00215	CbGeAlD
Vandetanib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00206	0.00207	CbGeAlD
Vandetanib—RET—Dopaminergic Neurogenesis—SLC6A3—Gilles de la Tourette syndrome	3.28e-05	0.0808	CbGpPWpGaD
Vandetanib—BLK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	1.84e-05	0.0454	CbGpPWpGaD
Vandetanib—FGR—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	1.84e-05	0.0452	CbGpPWpGaD
Vandetanib—YES1—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	1.48e-05	0.0365	CbGpPWpGaD
Vandetanib—RET—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	1.38e-05	0.034	CbGpPWpGaD
Vandetanib—KDR—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	1.17e-05	0.0287	CbGpPWpGaD
Vandetanib—LYN—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	1.1e-05	0.0272	CbGpPWpGaD
Vandetanib—FYN—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	1.09e-05	0.0268	CbGpPWpGaD
Vandetanib—PTK6—Focal Adhesion—MET—Gilles de la Tourette syndrome	1.03e-05	0.0253	CbGpPWpGaD
Vandetanib—LCK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	9.06e-06	0.0223	CbGpPWpGaD
Vandetanib—KDR—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	8.54e-06	0.021	CbGpPWpGaD
Vandetanib—SRC—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	8.02e-06	0.0197	CbGpPWpGaD
Vandetanib—ERBB3—a6b1 and a6b4 Integrin signaling—MET—Gilles de la Tourette syndrome	7.69e-06	0.0189	CbGpPWpGaD
Vandetanib—VEGFA—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	7.67e-06	0.0189	CbGpPWpGaD
Vandetanib—RET—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	6.04e-06	0.0149	CbGpPWpGaD
Vandetanib—EGFR—Extracellular vesicle-mediated signaling in recipient cells—MET—Gilles de la Tourette syndrome	5.92e-06	0.0146	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	5.65e-06	0.0139	CbGpPWpGaD
Vandetanib—EGFR—Arf6 signaling events—MET—Gilles de la Tourette syndrome	5.23e-06	0.0129	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	4.93e-06	0.0121	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	4.76e-06	0.0117	CbGpPWpGaD
Vandetanib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	4.76e-06	0.0117	CbGpPWpGaD
Vandetanib—FYN—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	4.7e-06	0.0116	CbGpPWpGaD
Vandetanib—EGFR—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	4.7e-06	0.0116	CbGpPWpGaD
Vandetanib—SRC—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	4.57e-06	0.0112	CbGpPWpGaD
Vandetanib—EGFR—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	4.52e-06	0.0111	CbGpPWpGaD
Vandetanib—SRC—Arf6 signaling events—MET—Gilles de la Tourette syndrome	4.46e-06	0.011	CbGpPWpGaD
Vandetanib—EGFR—a6b1 and a6b4 Integrin signaling—MET—Gilles de la Tourette syndrome	4.28e-06	0.0105	CbGpPWpGaD
Vandetanib—EGFR—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	4.06e-06	0.01	CbGpPWpGaD
Vandetanib—FMO3—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	4.06e-06	0.01	CbGpPWpGaD
Vandetanib—SRC—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	4.01e-06	0.00988	CbGpPWpGaD
Vandetanib—FMO1—Metabolism—HDC—Gilles de la Tourette syndrome	3.75e-06	0.00923	CbGpPWpGaD
Vandetanib—ABL1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	3.69e-06	0.00908	CbGpPWpGaD
Vandetanib—FYN—Semaphorin interactions—MET—Gilles de la Tourette syndrome	3.6e-06	0.00887	CbGpPWpGaD
Vandetanib—SRC—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	3.47e-06	0.00854	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	3.18e-06	0.00783	CbGpPWpGaD
Vandetanib—SRC—FGF signaling pathway—MET—Gilles de la Tourette syndrome	3.16e-06	0.00777	CbGpPWpGaD
Vandetanib—EPHA5—Axon guidance—MET—Gilles de la Tourette syndrome	2.92e-06	0.0072	CbGpPWpGaD
Vandetanib—ABL2—Axon guidance—MET—Gilles de la Tourette syndrome	2.92e-06	0.0072	CbGpPWpGaD
Vandetanib—VEGFA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	2.9e-06	0.00714	CbGpPWpGaD
Vandetanib—EPHA8—Axon guidance—MET—Gilles de la Tourette syndrome	2.82e-06	0.00694	CbGpPWpGaD
Vandetanib—FMO3—Metabolism—HDC—Gilles de la Tourette syndrome	2.68e-06	0.0066	CbGpPWpGaD
Vandetanib—BLK—Focal Adhesion—MET—Gilles de la Tourette syndrome	2.65e-06	0.00652	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	2.65e-06	0.00652	CbGpPWpGaD
Vandetanib—FGR—Focal Adhesion—MET—Gilles de la Tourette syndrome	2.64e-06	0.0065	CbGpPWpGaD
Vandetanib—EPHB6—Axon guidance—MET—Gilles de la Tourette syndrome	2.62e-06	0.00646	CbGpPWpGaD
Vandetanib—MAP2K5—Focal Adhesion—MET—Gilles de la Tourette syndrome	2.52e-06	0.0062	CbGpPWpGaD
Vandetanib—EPHA6—Axon guidance—MET—Gilles de la Tourette syndrome	2.47e-06	0.00607	CbGpPWpGaD
Vandetanib—KDR—Focal Adhesion—MET—Gilles de la Tourette syndrome	2.45e-06	0.00604	CbGpPWpGaD
Vandetanib—SRC—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	2.3e-06	0.00567	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	2.26e-06	0.00556	CbGpPWpGaD
Vandetanib—VEGFA—Focal Adhesion—MET—Gilles de la Tourette syndrome	2.21e-06	0.00543	CbGpPWpGaD
Vandetanib—EPHA5—Developmental Biology—MET—Gilles de la Tourette syndrome	2.09e-06	0.00514	CbGpPWpGaD
Vandetanib—ABL2—Developmental Biology—MET—Gilles de la Tourette syndrome	2.09e-06	0.00514	CbGpPWpGaD
Vandetanib—EPHA8—Developmental Biology—MET—Gilles de la Tourette syndrome	2.01e-06	0.00496	CbGpPWpGaD
Vandetanib—EPHB6—Developmental Biology—MET—Gilles de la Tourette syndrome	1.87e-06	0.00461	CbGpPWpGaD
Vandetanib—EPHA6—Developmental Biology—MET—Gilles de la Tourette syndrome	1.76e-06	0.00433	CbGpPWpGaD
Vandetanib—EGFR—Direct p53 effectors—MET—Gilles de la Tourette syndrome	1.73e-06	0.00425	CbGpPWpGaD
Vandetanib—PDGFRB—Focal Adhesion—MET—Gilles de la Tourette syndrome	1.62e-06	0.004	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.62e-06	0.00399	CbGpPWpGaD
Vandetanib—KDR—Axon guidance—MET—Gilles de la Tourette syndrome	1.6e-06	0.00394	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.57e-06	0.00388	CbGpPWpGaD
Vandetanib—FYN—Focal Adhesion—MET—Gilles de la Tourette syndrome	1.56e-06	0.00385	CbGpPWpGaD
Vandetanib—SRC—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	1.54e-06	0.0038	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.48e-06	0.00365	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.47e-06	0.00361	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.44e-06	0.00355	CbGpPWpGaD
Vandetanib—VEGFA—Axon guidance—MET—Gilles de la Tourette syndrome	1.44e-06	0.00354	CbGpPWpGaD
Vandetanib—YES1—Axon guidance—MET—Gilles de la Tourette syndrome	1.39e-06	0.00342	CbGpPWpGaD
Vandetanib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	1.37e-06	0.00338	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.36e-06	0.00334	CbGpPWpGaD
Vandetanib—EGFR—Focal Adhesion—MET—Gilles de la Tourette syndrome	1.35e-06	0.00333	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.34e-06	0.0033	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.32e-06	0.00324	CbGpPWpGaD
Vandetanib—ABCC1—Metabolism—HDC—Gilles de la Tourette syndrome	1.24e-06	0.00306	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.23e-06	0.00302	CbGpPWpGaD
Vandetanib—SRC—Focal Adhesion—MET—Gilles de la Tourette syndrome	1.15e-06	0.00284	CbGpPWpGaD
Vandetanib—KDR—Developmental Biology—MET—Gilles de la Tourette syndrome	1.14e-06	0.00281	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.12e-06	0.00277	CbGpPWpGaD
Vandetanib—ABCG2—Metabolism—HDC—Gilles de la Tourette syndrome	1.09e-06	0.0027	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.09e-06	0.00269	CbGpPWpGaD
Vandetanib—LYN—Axon guidance—MET—Gilles de la Tourette syndrome	1.04e-06	0.00255	CbGpPWpGaD
Vandetanib—ABL1—Axon guidance—MET—Gilles de la Tourette syndrome	1.03e-06	0.00254	CbGpPWpGaD
Vandetanib—VEGFA—Developmental Biology—MET—Gilles de la Tourette syndrome	1.03e-06	0.00253	CbGpPWpGaD
Vandetanib—AXL—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.03e-06	0.00253	CbGpPWpGaD
Vandetanib—FYN—Axon guidance—MET—Gilles de la Tourette syndrome	1.02e-06	0.00251	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.02e-06	0.0025	CbGpPWpGaD
Vandetanib—YES1—Developmental Biology—MET—Gilles de la Tourette syndrome	9.92e-07	0.00244	CbGpPWpGaD
Vandetanib—ALB—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	9.88e-07	0.00243	CbGpPWpGaD
Vandetanib—BMPR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.39e-07	0.00231	CbGpPWpGaD
Vandetanib—ABCC1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	9.24e-07	0.00228	CbGpPWpGaD
Vandetanib—EGFR—Axon guidance—MET—Gilles de la Tourette syndrome	8.82e-07	0.00217	CbGpPWpGaD
Vandetanib—FLT4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	8.59e-07	0.00212	CbGpPWpGaD
Vandetanib—ABCG2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	8.13e-07	0.002	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	7.55e-07	0.00186	CbGpPWpGaD
Vandetanib—SRC—Axon guidance—MET—Gilles de la Tourette syndrome	7.52e-07	0.00185	CbGpPWpGaD
Vandetanib—LYN—Developmental Biology—MET—Gilles de la Tourette syndrome	7.4e-07	0.00182	CbGpPWpGaD
Vandetanib—ABL1—Developmental Biology—MET—Gilles de la Tourette syndrome	7.37e-07	0.00181	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	7.33e-07	0.00181	CbGpPWpGaD
Vandetanib—FYN—Developmental Biology—MET—Gilles de la Tourette syndrome	7.29e-07	0.00179	CbGpPWpGaD
Vandetanib—MKNK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.12e-07	0.00175	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.91e-07	0.0017	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.83e-07	0.00168	CbGpPWpGaD
Vandetanib—ALB—Metabolism—HDC—Gilles de la Tourette syndrome	6.76e-07	0.00166	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.73e-07	0.00166	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.71e-07	0.00165	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.66e-07	0.00164	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.54e-07	0.00161	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.47e-07	0.00159	CbGpPWpGaD
Vandetanib—EGFR—Developmental Biology—MET—Gilles de la Tourette syndrome	6.29e-07	0.00155	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.28e-07	0.00155	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.25e-07	0.00154	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.09e-07	0.0015	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.09e-07	0.0015	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.05e-07	0.00149	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.02e-07	0.00148	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.88e-07	0.00145	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.85e-07	0.00144	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.68e-07	0.0014	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.68e-07	0.0014	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.47e-07	0.00135	CbGpPWpGaD
Vandetanib—SRC—Developmental Biology—MET—Gilles de la Tourette syndrome	5.37e-07	0.00132	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.29e-07	0.0013	CbGpPWpGaD
Vandetanib—ALB—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	5.02e-07	0.00124	CbGpPWpGaD
Vandetanib—RIPK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.79e-07	0.00118	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.45e-07	0.0011	CbGpPWpGaD
Vandetanib—MAP2K5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.38e-07	0.00108	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.36e-07	0.00107	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.32e-07	0.00106	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.29e-07	0.00106	CbGpPWpGaD
Vandetanib—KDR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.26e-07	0.00105	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.23e-07	0.00104	CbGpPWpGaD
Vandetanib—ERBB3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.22e-07	0.00104	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.17e-07	0.00103	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.03e-07	0.000991	CbGpPWpGaD
Vandetanib—EGFR—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.98e-07	0.000979	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.94e-07	0.000971	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.88e-07	0.000956	CbGpPWpGaD
Vandetanib—VEGFA—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.83e-07	0.000944	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.71e-07	0.000913	CbGpPWpGaD
Vandetanib—YES1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.7e-07	0.000912	CbGpPWpGaD
Vandetanib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	3.65e-07	0.000898	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.6e-07	0.000886	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.57e-07	0.00088	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.47e-07	0.000854	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.35e-07	0.000826	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.23e-07	0.000796	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.16e-07	0.000779	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.07e-07	0.000756	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.86e-07	0.000704	CbGpPWpGaD
Vandetanib—PDGFRB—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.82e-07	0.000694	CbGpPWpGaD
Vandetanib—LYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.76e-07	0.00068	CbGpPWpGaD
Vandetanib—FYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.72e-07	0.000669	CbGpPWpGaD
Vandetanib—EGFR—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.35e-07	0.000578	CbGpPWpGaD
Vandetanib—LCK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.26e-07	0.000557	CbGpPWpGaD
Vandetanib—SRC—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2e-07	0.000493	CbGpPWpGaD
